linjc16/ctgov huggingface dataset:
Safety & Efficacy of Omega-3 Fish Oil in Overweight Children & Adolescents

Study Overview
=================
Brief Summary
-----------------
Children with an excess in body weight, increase the risk of obesity-related co-morbidities and cardiovascular diseases. Childhood obesity may be due to diets laden with fat and lack of physical activity. Omega-3 fish oil is a supplementation that may promote a greater reduction of pro-inflammatory mediators; combined with exercise and nutritional regimens it may also help improve glycemic, lipid markers, and body composition in overweight children and adolescents.

Official Title
-----------------
Evaluation of the Safety and Efficacy of Omega-3 Fish Oil Dietary Supplementation in Biometric Measurement, Lipid Profile, Serum Markers for Inflammation, and Insulin Resistance in Overweight Children and Adolescents

Conditions
-----------------
Overweight, Obesity

Intervention / Treatment
-----------------
* Drug: Supplement: Omega-3 Fish Oil
* Behavioral: Multi-Disciplinary Nutrition & Exercise program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 8-18 years old BMI ≥95th percentile Patient & parent/guardian consent to participate Attendance of Risk Factor Reduction lifestyle modification program Exclusion Criteria: Major surgical Procedure within 1 year Significant cardiovascular disease or other morbidity that preclude patients from following dietary regimen or exercising. Mentally Challenged Currently taking fish oil supplements, unless 1 month wash-out period is achieved. Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Supplement: Omega-3 Fish Oil|nan|
|Behavioral: Multi-Disciplinary Nutrition & Exercise program|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare effects between Omega 3 fish oil and placebo | To compare the effect of Omega 3 fish oil dietary supplementation versus placebo on biometric measurement, lipid profile, serum markers for inflammation and insulin resistance in overweight children and adolescents undergoing treatment with a low-glycemic load diet and exercise. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare effects between Omega 3 fish oil and placebo | To compare the changes in weekly physical activity, biometrics measurements and body mass index between overweight children and adolescents receiving Omega 3 fish oil supplementation versus placeb | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Overweight, Obesity, Fish Oil
mNGS Was Applied to the Study of Pathogen Identification, Precision Medication and Efficacy Evaluation of Infected Patients

Study Overview
=================
Brief Summary
-----------------
1) prospectively collected the patients with the proposed infection, confirmed the infection or excluded the infection through mNGS detection combined with traditional pathogen detection methods and clinical characteristics, compared the detection performance of mNGS and traditional methods, and explored the significance of mNGS microbial map characteristics for the diagnosis/exclusion of infection; 2) real-time dynamic monitoring of the pathogen and microecology of infected patients during the targeted drug use, and evaluation of the efficacy in combination with other indicators; 3) to explore the significance of the number of pathogen sequences before the clinical withdrawal of drugs to the clinical practice.

Official Title
-----------------
mNGS Was Applied to the Study of Pathogen Identification, Precision Medication and Efficacy Evaluation of Infected Patients

Conditions
-----------------
mNGS

Intervention / Treatment
-----------------
* Diagnostic Test: mNGS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 75 years old expected length of stay in ICU was > 24 h suspected infected patients (PSI or CPIS, qSOFA or SIRS) Exclusion Criteria: Pregnant and lactating women Who has not signed the informed consent the researchers considered that others were not suitable for the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Precision therapy<br> | Diagnostic Test: mNGS<br>* Metagenomics second generation sequencing technology<br>|
| No Intervention: control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28-day mortality | 28-day mortality | 28 days |
Validation of the English Version of the FIMA Questionnaire

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to determine the validity and reliability of the English version of the Questionnaire for Health-Related Resource Use in an Elderly Population (FIMA).

Official Title
-----------------
Validation of the English Version of the FIMA Questionnaire

Conditions
-----------------
Elderly Persons

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -65+. Exclusion Criteria: younger than 65+ severe visual impairment severe auditory impairment poor command of English no consent to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|Completing the questionnaire for health-related resource use in the elderly population (FIMA) by the elderly people|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Good validity and reliability of the FIMA | The Questionnaire for Health-Related Resource Use in an Elderly Population is a self-administered questionnaire, which assesses nine features and contains 28 questions altogether: questions 1-18 refer directly to the use of medical and nonmedical services by the elderly, whereas questions 19-28 concern the sociodemographic characteristics of the person surveyed as well as an assessment of questionnaire difficulty and time spent completing it. A total of minimum 60 elderly people, 65 years of age and older, who will be admitted to the Gessler Clinic, USA California, are recruited. All patients will be screening twice for health-related resource use, using the English version of the Questionnaire for Health-Related Resource Use in an Elderly Population. Each patient will be evaluated twice: once within 48 hours at admission and once after two weeks. The English FIMA demonstrate very good test-retest reliability, good validity, and ease of use for elderly people. | 11.2019-12.2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
resource use, assessment, elderly
Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
Furosemide is an old drug that has been used frequently in the postoperative period of kidney transplantation, aiming to achieve adequate urine output. There is no previous study that directly evaluate the urine response to standardized dose of furosemide in the postoperative period. The objective is to measure the urine output after standardized dose of furosemide is delivered, as a biomarker to predict the graft function in perioperative period.

Official Title
-----------------
Furosemide Stress Test as a Marker of Postoperative Kidney Allograft Function

Conditions
-----------------
Kidney Function, Kidney Transplant; Complications, Delayed Graft Function

Intervention / Treatment
-----------------
* Drug: Furosemide Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Deceased donor kidney transplantation at KCMH informed consent is accepted Exclusion Criteria: Known allergy to furosemide Surgical complication of allograft Urgently needed for dialysis (refractory hypervolemia, uremic symptoms, and hyperkalemia)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Furosemide<br>Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft. Urine output will be recorded hourly for 6 hours. | Drug: Furosemide Injection<br>* Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urine output | Urine output per hour (milliliters/hour) after furosemide injection | 6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delayed graft function | Delayed graft function is defined by the necessity of dialysis within the first week after kidney transplantation. (yes/no) | 7 days | 
| Creatinine reduction ratio | Ratio of serum creatinine at postoperative day 7 and 14 to day-zero creatinine | At postoperative day 0,7 and 14 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
furosemide stress test, kidney transplantation, urine output, perioperation, delayed graft function
Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension

Study Overview
=================
Brief Summary
-----------------
To assess the correlation between pulmonary IV-OCT and pulmonary IV-US measurements and standard PAH clinical measures of disease progression and the relative sensitivity of the techniques to change.

Official Title
-----------------
Repeatability of Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IV-US) in Pulmonary Arterial Hypertension

Conditions
-----------------
Pulmonary Arterial Hypertension

Intervention / Treatment
-----------------
* Procedure: Patients with Pulmonary Arterial Hypertension


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: With confirmed diagnosis of PAH Group 1 according to the ESC/ERS Guidelines With severe disease, defined as Class II- III of the modified WHO functional classes in the ESC/ERS Guidelines Exclusion Criteria: That according to investigator criteria cannot participate in the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pulmonary Arterial Hypertension<br>Patients with Pulmonary Arterial Hypertension | Procedure: Patients with Pulmonary Arterial Hypertension<br>* 2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Image measurements | Repeat acquisitions to be made in the same regions and in locations | 12 months |
COVID-19 Immune Repertoire Sequencing

Study Overview
=================
Brief Summary
-----------------
This concerns a single-center prospective interventional cohort study. Laboratory-confirmed COVID-19 patients will be asked to donate blood at at least two different timepoints. This will allow us to investigate T and B cell evolutions during the course of infection and recovery. The expected duration of the study is four months or the total duration of the SARS-CoV-2 circulation in Belgium (whichever is shortest).

Official Title
-----------------
COVID-19 Immune Repertoire Sequencing

Conditions
-----------------
COVID, SARS-CoV 2, Corona Virus Infection, RDT, B Cell

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: laboratory confirmed COVID-19 acute infection be older than 18 years of age be hospitalized at the UZA willing and able to provide written informed consent by the participant or its legal representative (for instance in case of medical incapacitation) Exclusion Criteria: younger than 18 years old Ambulatory patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| provide proof-of-concept that (longitudinal) B cell repertoire mining allows identification of emerging virus specific B cell receptor variable regions. |  | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| study evolutions in B and T cell repertoires to understand COVID-19 specific immune responses fundamentally. |  | every 7 days during hospitalization a bloodsample is taken | 
| clinical and epidemiological description of UZA hospitalized COVID-19 patients |  | at hospitalization |
SMART Protocol vs Antagonist Protocol in IVF

Study Overview
=================
Brief Summary
-----------------
This retrospective study aims to assess the effect of adding letrozole in patients who have previously undergone an IVF cycle with either an antagonist or short protocol, with patients who have undergone a second cycle of IVF with an antagonist or short protocol without the addition of letrozole.

Detailed Description
-----------------
A limited number of studies suggest that the addition of letrozole to gonadotropins for IVF is associated with an increase in oocyte count, blastocyst count and implantation rate. These differences are presumed to be caused by an increase in intra-ovarian androgens associated with the addition of letrozole. In patients with reduced ovarian reserve or reduced oocyte quality in the previous cycle, supplementation with of letrozole has the potential to increase oocyte count or oocyte quality, thereby resulting in more transferable blastocysts. The antagonist stimulation protocol with the addition of letrozole is commonly referred to as the SMART protocol (Stimulation with Minimal Adverse effects, Retrieval and Transfer

Official Title
-----------------
Effect of the Addition of Letrozole in in Vitro Fertilization (IVF) Following a Prior Failed IVF Cycle With an Antagonist or Short Protocol Without Letrozole

Conditions
-----------------
Diminished Ovarian Reserve

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for the SMART IVF protocol: Women between the ages of 20 and 42 inclusively Women proceeding with a SMART IVF protocol following an antagonist IVF protocol between 2010 and 2020 (study group) or women proceeding with an antagonist protocol following an antagonist IVF protocol between 2010 and 2020 (control group) Delay of 1 year between both IVF cycle Exclusion Criteria: Women undergoing fertility preservation Oocyte donation IVF cycles Diagnosed severe male factor requiring surgical sperm extraction (micro-tese or TESA)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Antagonist - SMART<br>Women who have had a SMART IVF stimulation cycle with Letrozole after a failed antagonist IVF stimulation cycle between 2010 and 2020. | |
| Antagonist - Antagonist<br>Women who have had an antagonist stimulation IVF cycle after a previously failed antagonist IVF stimulation cycle between 2010 and 2020. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of utilizable blastocysts obtained | Comparing 2 different IVF cycle protocols in terms of total dose of gonadotropins used | approximately 20 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF, Fertility issues
Low-dose Cortisol in Chronic Posttraumatic Stress Disorder

Study Overview
=================
Brief Summary
-----------------
The aim of this prospective, double-blind, placebo-controlled, cross-over study is to determine the therapeutic efficacy of low-dose cortisol for symptoms of chronic posttraumatic stress disorder.

Official Title
-----------------
Low-dose Cortisol in Chronic Posttraumatic Stress Disorder

Conditions
-----------------
Posttraumatic Stress Disorder

Intervention / Treatment
-----------------
* Drug: Cortisol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female and male patients with chronic PTSD due to adult trauma; PTSD is diagnosed according to the DSM-IV, as measured with the CAPS Age between 18 and 60 Exclusion Criteria: History of disease states representing contraindications to glucocorticoid therapy (tuberculosis, gastritis, gastric- and duodenal ulcers, Cushing's disease, osteoporosis, hypertension, pregnancy (to exclude with a pregnancy test) and lactation, glaucoma, diabetes mellitus, thrombophilia, acute or chronic infections, hyperthyroidism, cirrhosis) Severe or chronic somatic diseases Topic glucocorticoid therapy (for large skin parts) Inhaled glucocorticoids Current psychotic, bipolar, substance-related, or severe personality disorder Current severe depressive disorder Severe cognitive impairment or a history of organic mental disorder Evidence of PTSD or depression immediately prior to the index trauma Prominent current suicidal or homicidal ideation Asylum seeking status Body weight >20% above or below normal range Changes in psychopharmacologic or psychotherapeutic management less than 8 weeks before start of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cortisol|Cortisol 10 mg/d for 3 months|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CAPS CGI |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PTSD, cortisol, memory, treatment
Reducing Post-tonsillectomy Pain by Tonsil Pillars Suturing.

Study Overview
=================
Brief Summary
-----------------
comparing post-tonsillectomy pain with and without suturing tonsil pillars to investigate whether suturing tonsil pillars reduces the pain of post-tonsillectomy.

Official Title
-----------------
Reducing Post-tonsillectomy Pain by Tonsil Pillars Suturing.

Conditions
-----------------
Post - Tonsillectomy Pain

Intervention / Treatment
-----------------
* Procedure: tonsil pillars suturing
* Procedure: tonsillectomy without tonsil pillars suturing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 and over. patients with tonsillectomy indication due to chronic Tonsillitis. Exclusion Criteria: patients with tonsillectomy indication without chronic tonsillitis ( due to other causes). chronic disease, chronic neurology disease. chronic psychology disease. bleeding tendency.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: patients with post - tonsillectomy suturing tonsil pillars<br> | Procedure: tonsil pillars suturing<br>* The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.<br>|
| Placebo Comparator: patients without post - tonsillectomy suturing tonsil pillars<br> | Procedure: tonsillectomy without tonsil pillars suturing<br>* tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reducing Post-tonsillectomy Pain by Tonsil Pillars Suturing. | two patients' group in this study , one group will have a Tonsil pillars suturing after the tonsillectomy and the second group will not have this technique after the tonsillectomy, then patience should answer a post pain tonsillectomy questionnaire , by the questionnaire and the checkups to compare how each group affected ( using SPSS program and Statistics Methods. | 1 year |